2024-03-01 13:17:00
Evonik will market a new PEG
Evonik has finalized an agreement with the University of Mainz (Germany) to commercialize a new type of polyethylene glycol (or PEG) called randomized PEG. Compared to a traditional PEG, this development offers similar properties but a different structure to improve the immunogenicity profile.
Nanolipids are notably used to serve as shuttles for mRNA vaccines, including the Covid-19 vaccine, but are also used in other forms of innovative therapies. Evonik will leverage these new products for its platform dedicated to lipids and nanolipids with availability from the second half of 2024.
I will tell you
source
Faced with this innovation coming from the academic world, Evonik “ immediately recognized the potential for expanded formulation options and the benefit this might bring to our customers », underlined Thomas Riermeier, director of the Health Care division of Evonik. The company has made nanolipids one of its priorities. It has opened a site dedicated to their GMP production in Hanau, Germany and is planning a facility focused on this product in Lafayette (United States).
UCB signs a gloomy year
UCB has just published its annual results and announces a turnover of 5.25 billion euros in 2023, down 5% compared to 2022. This variation is explained in particular by the loss of exclusivity of Vimpat (-65%) in the United States and Europe, and Keppra (-13%) in Japan. A decline that was unable to offset the strong growth of three of its assets, including Bimzelx once morest psoriasis (+ 323%). The Belgian laboratory’s flagship active ingredient, Cimzia (certolizumab pegol), indicated once morest rheumatoid arthritis, posted sluggish performance (€2.08 billion in sales).
The year 2023 will, however, have been marked by multiple drug approvals as Jean-Christophe Tellier, CEO of UCB, explains: “ Over the past 14 months, we have obtained 14 approvals, across 6 patient populations and across 3 continents », he rejoiced. Enough to hope for better results in the coming years. For 2024, UCB hopes to see its turnover increase to reach 5.5 to 5.7 billion euros.
Crossject raises 12 million euros
Crossject announced that it had obtained financing of 12 million euros from an entity managed by Heights Capital Management in two parts, in the form of convertible bonds issued into new shares or a loan at 7%. The Dijon biotech company specializing in the development of needle-free auto-injectors for emergency situations, particularly in the event of an epileptic seizure, plans to use these funds for the industrialization and commercialization of its technology.
« It is a sign of confidence in our industrial and commercial progress, particularly in North America », rejoices Patrick Alexandre, CEO of Crossject. These funds are in addition to those already paid by the American organization Barda, following the contract entered into with them in 2022, as well as “ other recently secured funding and commercial revenues linked to new or existing partnerships », adds Patrick Alexandre.
Selected for you
1709308980
#bref #Evonik #UCB #Crossject
